Masè G, Ros S, Gemma A, Bonfigli L, Carraro N, Cazzato G, Rolfo M, Zanconati F, Sepcic J, Jurjevic A, Pirulli D, Boniotto M, Zezlina S, Crovella S, Amoroso A
Department of Neurology, University of Trieste and "Cattinara" Hospital, Trieste, Italy.
J Neurol Sci. 2001 Oct 15;191(1-2):11-8. doi: 10.1016/s0022-510x(01)00625-6.
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder. The mutations of Cu/Zn superoxide dismutase gene (SOD1) are responsible for familial ALS. We investigated a large family of Istro-Rumanian origin characterized by an autosomal dominant ALS occurring in 18 cases (three of which are still alive) throughout six generations.
Clinical data were available for nine patients from the 2nd generation onward, among which one contained the neuropathological details. The mean age at onset of the disease (+/-SD) was 57.3+/-8.9 years (range 49-72), while the duration of the disease spanned over a length of time equal to 4.9+/-1.96 years (range 1.5-7). The analysis of the coding region of SOD1 was done by PCR and direct sequencing. The SOD1 activity was measured by using the red and mononuclear cells belonging to three of the patients.
The leu144phe mutation of SOD1 was identified in four patients while a normal sequence was found in five healthy related subjects. The molecular defect was responsible for a decrease in SOD1 activity. Most of patients in this family presented clinical manifestations of ALS (in particular, the lower limb onset variant) not as severe as typical ALS caused by other SOD1 mutations. However, one patient suffering from hyperthyroidism for 17 years, showed an early onset and a rapidly progressing ALS coupled with dementia.
We described a large family with a relatively not severe phenotype of ALS (due to a leu144phe SOD1 mutation) that was compromised in one patient by a concomitant hyperthyroidism.
肌萎缩侧索硬化症(ALS)是一种进行性神经疾病。铜/锌超氧化物歧化酶基因(SOD1)突变是家族性ALS的病因。我们研究了一个起源于伊斯特罗 - 罗马尼亚的大家族,其特征为常染色体显性遗传的ALS,在六代中有18例发病(其中3例仍在世)。
从第二代起有9名患者的临床数据,其中1例包含神经病理学细节。疾病发病的平均年龄(±标准差)为57.3±8.9岁(范围49 - 72岁),而疾病持续时间为4.9±1.96年(范围1.5 - 7年)。通过聚合酶链反应(PCR)和直接测序对SOD1编码区进行分析。使用3例患者的红细胞和单核细胞测量SOD1活性。
在4例患者中鉴定出SOD1的leu144phe突变,而在5名健康相关受试者中发现正常序列。分子缺陷导致SOD1活性降低。该家族中的大多数患者表现出的ALS临床表现(特别是下肢起病型)不如其他SOD1突变引起的典型ALS严重。然而,1例患有17年甲状腺功能亢进症的患者表现出疾病早发、快速进展的ALS并伴有痴呆。
我们描述了一个具有相对不严重ALS表型(由于SOD1的leu144phe突变)的大家族,其中1例患者因同时患有甲状腺功能亢进症而病情加重。